- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Extendicare Announces 2017 Year End Results
Extendicare (TSX:EXE) reported results for the fourth quarter and year ended December 31, 2017. Results are presented in Canadian dollars unless otherwise noted. As quoted in the press release: Revenue of $281.4 million up 1.6% or $4.5 million reflecting growth from all divisions moderated by impact of prior period funding of $2.2 million received in …
Extendicare (TSX:EXE) reported results for the fourth quarter and year ended December 31, 2017. Results are presented in Canadian dollars unless otherwise noted.
As quoted in the press release:
- Revenue of $281.4 million up 1.6% or $4.5 million reflecting growth from all divisions moderated by impact of prior period funding of $2.2 million received in Q4 2016.
- Net operating income of $35.6 million up $1.9 million or 5.5% reflecting increased contributions from all divisions partially offset by favourable prior period accrual adjustments of $1.6 million recorded in Q4 2016.
- Earnings from continuing operations of $10.3 million ($0.12 per basic share) down $2.9 million, with improvements in operations offset by an unfavourable change in fair value adjustments and foreign exchange and lower interest revenue related to U.S. sale deferred consideration received in 2016.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â